Effective treatment of a platinum-resistant cutaneous squamous cell carcinoma case by EGFR pathway inhibition.

Mol Clin Oncol 2018 Jul 21;9(1):30-34. Epub 2018 May 21.

Medical Oncology Sant'Andrea Hospital, I-00189 Rome, Italy.

Cutaneous squamous cell carcinoma (cSCC) is the second most common type of non-melanoma skin cancer. Platinum-based regimens have been an integral part of palliative care for patients with locally advanced or metastatic disease. There is no evidence of efficacy for later lines of chemotherapy and no targeted therapy has been introduced as 'standard of care'. Here we report on the case of an elderly cSCC patient, resistant to conventional therapy, however successfully treated with anti-epidermal growth factor receptor (EGFR) agent (Cetuximab) in addition to a daily dose of Curcumin phospholipid. The patient responded to treatment and experienced no recurrence for 11 months with only minor skin-related toxicity. To our knowledge, this is the first report of clinical evidence that an anti EGFR targeted therapy with a daily oral dose of Curcumin phospholipid is well tolerated and results in a highly effective disease control in a heavily pretreated cSCC patient.

Download full-text PDF

Source
http://dx.doi.org/10.3892/mco.2018.1634DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6031894PMC
July 2018
5 Reads

Publication Analysis

Top Keywords

squamous cell
8
cutaneous squamous
8
cell carcinoma
8
targeted therapy
8
curcumin phospholipid
8
dose curcumin
8
cscc patient
8
receptor egfr
4
growth factor
4
anti-epidermal growth
4
factor receptor
4
agent cetuximab
4
daily dose
4
addition daily
4
cetuximab addition
4
treated anti-epidermal
4
egfr agent
4
patient resistant
4
introduced 'standard
4
'standard care'
4

Similar Publications